Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: The risk of Cushing syndrome (CS) patients experiencing a thrombotic event (TE) is significantly higher (odds ratio; OR 18%) than that of the general population. However, there are currently no anticoagulation guidelines. Methods: A retrospective, single-center, longitudinal study of patients undergoing all types of treatment—surgical (pituitary, unilateral, and bilateral adrenalectomy) and medical treatment—was undertaken. TEs were recorded at any point up until last patient follow-up; myocardial infarction (MI), deep venous thrombosis (DVT), and pulmonary embolism (PE) or stroke. Patients’ doses and complications of anticoagulation were recorded. Results: Included were 208 patients; a total of 165 (79.3%) were women, and mean age at presentation was 44 ± 14.7 years. Thirty-nine (18.2%) patients had a TE; extremity DVT (38%), cerebrovascular accident (27%), MI (21%), and PE (14%). Of 56 TEs, 27 (48%) were arterial and 29 (52%) were venous. Patients who underwent bilateral adrenalectomy (BLA) had an odds ratio of 3.74 (95% CI 1.69-8.27) of developing a TE. Of patients with TEs, 40.5% experienced the event within the first 60 days after surgery. Baseline 24-hour urinary free cortisol levels did not differ in patients with or without TE after BLA. Of 197 patients who underwent surgery, 50 (25.38%) received anticoagulation after surgery, with 2% having bleeding complications. Conclusions: The risk of TEs in patients with CS was approximately 20%. Many patients had more than 1 event, with higher risk 30 to 60 days postoperatively. The optimal prophylactic anticoagulation duration is unknown, but most likely needs to continue up to 60 days postoperatively, particularly after BLA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“Cushing syndrome (CS) is associated with a 2- to 4-fold higher mortality rate compared to the general population when not appropriately treated (1-4), largely because of an increase in cardiovascular disease and infection (1, 5-7).”
BackgroundTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419 · cited 7×
“Cushing syndrome (CS) is associated with a 2- to 4-fold higher mortality rate compared to the general population when not appropriately treated (1-4), largely because of an increase in cardiovascular disease and infection (1, 5-7).”
BackgroundInfluentialHypercoagulable State in Cushing’s Syndrome: A Systematic Review
Van Zaane, B., Nur, E., Squizzato, A., Dekkers, O. M., Twickler, M. (. B., Fliers, E., Gerdes, V. E. A., Büller, H. R., & Brandjes, D. P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0290 · Cited by 216
Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208 · cited 3×
“Furthermore, a multicenter cohort study reported that the risk of postoperative VTE was significantly higher in patients with Cushing disease (CD) compared to patients undergoing pituitary surgery for a nonfunctioning pituitary adenoma, suggesting that the high risk for postoperative VTE in patients with CS is cortiso…”
BackgroundResultMortality and morbidity in Cushing's syndrome in New Zealand
Bolland, M. J., Holdaway, I. M., Berkeley, J. E., Lim, S., Dransfield, W. J., Conaglen, J. V., Croxson, M. S., Gamble, G. D., Hunt, P. J., & Toomath, R. J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04124.x · Cited by 182
Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up
Ntali, G., Asimakopoulou, A., Siamatras, T., Komninos, J., Vassiliadi, D., Tzanela, M., Tsagarakis, S., Grossman, A. B., Wass, J. A. H., & Karavitaki, N. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0569 · Cited by 149
Giordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04055.x · Cited by 122
Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center
Yaneva, M., Kalinov, K., & Zacharieva, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0320 · Cited by 93 · cited 2×
“Standardized mortality ratio decreases in patients with CS who are successfully treated but does not return to that of the normal population (1, 2, 4, 5).”
Background
Research works printed but not linked: 35
- Clayton, 2011, Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J Clin Endocrinol Metab., 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
- Pivonello, 2016, Complications of Cushing’s syndrome: state of the art, Lancet Diabetes Endocrinol., 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
- Johannesdottir, 2013, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study, JAMA Intern Med., 173, 743, 10.1001/jamainternmed.2013.122 · DOI · Paper page
- Świątkowska-Stodulska, 2015, Activity of selected coagulation factors in overt and subclinical hypercortisolism, Endocr J., 62, 687, 10.1507/endocrj.EJ14-0539 · DOI
- Fatti, 2000, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome, J Endocrinol Invest., 23, 145, 10.1007/BF03343697 · DOI
- Jenkins, 2012, Elevated factor VIII levels and risk of venous thrombosis, Br J Haematol., 157, 653, 10.1111/j.1365-2141.2012.09134.x · DOI · Paper page
- Cavusoglu, 2011, Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome, Am J Med., 124, 724, 10.1016/j.amjmed.2011.02.040 · DOI
- Pecori Giraldi, 2011, Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing’s disease, Br J Clin Pharmacol., 71, 132, 10.1111/j.1365-2125.2010.03812.x · DOI
- van der Pas, 2012, The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy, J Clin Endocrinol Metab., 97, 1303, 10.1210/jc.2011-2753 · DOI · Paper page
- Karamouzis, 2015, Enhanced oxidative stress and platelet activation in patients with Cushing’s syndrome, Clin Endocrinol (Oxf)., 82, 517, 10.1111/cen.12524 · DOI
- Greenhill, 2016, Pituitary disease: inflammation in patients with Cushing disease, Nat Rev Endocrinol., 12, 687, 10.1038/nrendo.2016.170 · DOI
- Wagner, 2018, Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing’s syndrome: a systematic meta-analysis, Front Endocrinol (Lausanne)., 9, 805, 10.3389/fendo.2018.00805 · DOI · Paper page
- Koutroumpi, 2013, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile, Pituitary., 16, 175, 10.1007/s11102-012-0398-4 · DOI
- Semple, 1999, Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing’s disease, J Neurosurg., 91, 175, 10.3171/jns.1999.91.2.0175 · DOI · Paper page
- Rees, 2002, Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission, Clin Endocrinol (Oxf)., 56, 541, 10.1046/j.1365-2265.2002.01511.x · DOI · Paper page
- Flevas, 2018, Thromboembolism prophylaxis in orthopaedics: an update, EFORT Open Rev., 3, 136, 10.1302/2058-5241.3.170018 · DOI · Paper page
- Bjørnarå, 2006, Frequency and timing of clinical venous thromboembolism after major joint surgery, J Bone Joint Surg Br., 88, 386, 10.1302/0301-620X.88B3.17207 · DOI
- Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients, J Clin Endocrinol Metab., 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
- Petersenn, 2014, High variability in baseline urinary free cortisol values in patients with Cushing’s disease, Clin Endocrinol (Oxf)., 80, 261, 10.1111/cen.12259 · DOI · Paper page
- van Haalen, 2015, Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis, Eur J Endocrinol., 172, R143, 10.1530/EJE-14-0556 · DOI · Paper page
- Kastelan, 2013, Hypercoagulable state in Cushing’s syndrome is reversible following remission, Clin Endocrinol (Oxf)., 78, 102, 10.1111/j.1365-2265.2012.04479.x · DOI
- Guarnotta, 2017, The degree of urinary hypercortisolism is not correlated with the severity of Cushing’s syndrome, Endocrine., 55, 564, 10.1007/s12020-016-0914-9 · DOI
- Valassi, 2018, Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN, Eur J Endocrinol., 178, 399, 10.1530/EJE-17-0997 · DOI · Paper page
- Coelho, 2015, Adverse effects of glucocorticoids: coagulopathy, Eur J Endocrinol., 173, M11, 10.1530/EJE-15-0198 · DOI
- Small, 1983, Thromboembolic complications in Cushing’s syndrome, Clin Endocrinol (Oxf)., 19, 503, 10.1111/j.1365-2265.1983.tb00025.x · DOI
- Babic, 2019, Is VTE prophylaxis necessary on discharge for patients undergoing adrenalectomy for Cushing syndrome?, J Endocr Soc., 3, 304, 10.1210/js.2018-00278 · DOI
- van der Pas, 2013, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment, Clin Endocrinol (Oxf)., 78, 481, 10.1111/cen.12094 · DOI · Paper page
- Boscaro, 2002, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome, J Clin Endocrinol Metab., 87, 3662
- Barbot, 2015, Perioperative thromboprophylaxis in Cushing’s disease: what we did and what we are doing?, Pituitary., 18, 487, 10.1007/s11102-014-0600-y · DOI
- Smith, 2015, Defensive medicine in neurosurgery: does state-level liability risk matter?, Neurosurgery., 76, 105, 10.1227/NEU.0000000000000576 · DOI
- Lang, 2015, The serum- & glucocorticoid-inducible kinase in the regulation of platelet function, Acta Physiol (Oxf)., 213, 181, 10.1111/apha.12334 · DOI
- Casonato, 1999, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome, Blood Coagul Fibrinolysis., 10, 145, 10.1097/00001721-199904000-00006 · DOI · Paper page
- Manetti, 2010, Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery, Eur J Endocrinol., 163, 783, 10.1530/EJE-10-0583 · DOI · Paper page
- Zilio, 2016, A venous thromboembolism risk assessment model for patients with Cushing’s syndrome, Endocrine., 52, 322, 10.1007/s12020-015-0665-z · DOI
- Pace, 2017, European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma, Lancet Oncol., 18, e330, 10.1016/S1470-2045(17)30345-5 · DOI · Paper page
Cited by
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationClinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Self-citationApproach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
Vogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
Metadata
- Authors
- Suarez, M. G., Stack, M., Hinojosa-Amaya, J. M., Mitchell, M. D., Varlamov, E. V., Yedinak, C. G., Cetas, J. S., Sheppard, B., & Fleseriu, M.
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2019-12-15
- Volume
- 4
- Issue
- 2
- Pages
- bvz033-bvz033
- ISSN
- 2472-1972 (ISSN-L)
- OpenAlex
- W2996524239
- Cited by
- 68
- References
- 10
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study. https://app.cochat.ai/papers/10.1210/jendso/bvz033
- The paper
- Suarez, M. G., Stack, M., Hinojosa-Amaya, J. M., Mitchell, M. D., Varlamov, E. V., Yedinak, C. G., Cetas, J. S., Sheppard, B., & Fleseriu, M. (2020). Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study. Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvz033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.